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I N T R O D U C T I O N
Atheromatosis is a multifactorial, inflammatory, fibroproliferative process of the artery wall with a high prevalence in chronic kidney disease (CKD), and it is one of the most common forces behind cardiovascular disease (CVD) [1, 2] . Individuals with CKD are at a higher risk of cardiovascular events than the general population [3] , but risk assessment in this population is difficult due to the lack of accuracy of current algorithms [4] . Nonetheless, the use of non-invasive vascular ultrasound imaging is an emerging tool with promising outcomes for cardiovascular risk assessment in CKD patients [5, 6] .
Carotid intima-media thickness (IMT), defined as the distance between the intimal-luminal and medial-adventitial interfaces of the artery wall, is a reliable surrogate marker with predictive value for cardiovascular events in the general [7] and CKD populations [6, 8] . In the early stages of atheromatosis, IMT increases before the development of plaque and it has been shown that individuals in whom IMT progresses faster are at a higher risk for future events [9] .
CKD is a multifactorial complex disease involving a wide range of metabolic alterations. Besides traditional cardiovascular risk factors, specific renal factors can play an important role in the early onset of CVD, explaining the excess risk attributable to kidney disease [10] . One of the main complications secondary to CKD is the dysregulation of mineral metabolism parameters, namely CKD-related mineral and bone disorder (MBD) [11] . hormones, the main regulators of calcium and phosphorus homeostasis, have an important effect on many organs and tissues, including the vascular vessels [12] . These alterations have been associated with an increased risk of cardiovascular events in dialysis patients [13, 14] . Nevertheless, CKD-MBD begins early in the course of CKD and little is known about its predictive value in subclinical atheromatosis progression [15] . Studies examining the relationship between CKD and IMT commonly focus on analysing cardiovascular risk factors associated with increased IMT [16, 17] , and there are scarce data about IMT progression in this specific population [9, 15, 18] . Identification of the specific factors that influence IMT progression in CKD could uncover new therapeutic strategies to decrease cardiovascular morbidity and mortality. Therefore, the aim of the present study was to analyse the factors associated with accelerated progression of common carotid intima-media thickness (CCIMT) in 1152 patients with stage 3-5D CKD, after 2 years of follow-up.
M A T E R I A L S A N D M E T H O D S

Study population
NEFRONA is an observational, multicentre, prospective cohort study designed to evaluate the subclinical atherosclerosis burden and the predictive value of biomarkers and surrogate measures on CVD in CKD patients. Its design and baseline characteristics have been described previously [19, 20] . Briefly, between 2010 and 2012, the NEFRONA study enrolled 2445 patients free from clinical CVD who were 18-76 years of age from 81 Spanish hospitals and dialysis clinics. From the study cohort of 2445 patients with CKD, 888 patients were excluded from the 24-month follow-up visit. Namely, patients who had stenotic carotid plaque or had an ankle-brachial index <07 (n ¼ 118), had a cardiovascular event during the 2-year follow-up (n ¼ 97), received a renal transplant (n ¼ 371), died from noncardiovascular causes (n ¼ 58) or were second visit nonattendees (n ¼ 244) were excluded from the follow-up visit. Some patients who attended the 24-month ultrasound visit were excluded because of missing CCIMT values (n ¼ 31) or had a plaque located in the common carotid artery (CCA) at baseline (n ¼ 154) or incomplete laboratory data (n ¼ 220). Finally, a total of 1552 participants were included in the present study ( Figure 1 ).
All participants were included after providing informed consent. The study was approved by each local hospital ethics committee.
Carotid ultrasound
High-resolution B-mode ultrasound was conducted using a standardized protocol and following the recommendations of the Mannheim Consensus [21] . CCIMT was measured at the far wall of both CCAs in plaque-free segments 1 cm proximal to the carotid bulb and taking into account the mean value of 150 measurements performed on a 10 mm segment. The presence of atheromatous plaques was defined as an IMT !1.5mm protruding into the lumen. Ultrasound explorations were carried out by the same itinerant team of five trained technicians. Images were analysed in a blinded fashion by a single reader from the Unit for the Detection and Treatment of Atherothrombotic Diseases (Hospital Universitari Arnau de Vilanova, Lleida, Spain). For the examinations, a computersupported image analysis system (Vivid BT09 and the semiautomatic software EchoPAC Dimension, General Electric) was used.
To assess the quality of the measurements, a sample of 20 individuals was measured three to five times on different days, obtaining an intraclass correlation coefficient of 0.93.
CCIMT progression was defined as the difference between CCIMT at baseline and at 24 months for each side, which was then averaged and normalized as change per year. On the basis of the study aim, accelerated CCIMT progression was defined as an IMT change !75th percentile.
Clinical and biochemical data
At recruitment, the itinerant team reviewed the hospital medical records of each selected subject and collected demographic data and a medical history of comorbidities and treatments. Anthropometric data and vital signs were obtained by the itinerant team using standardized methods [22] . Biochemical parameters were obtained from a routine fasting blood test performed not more than 3 months (either before or after) from the vascular exploration. Furthermore, in dialysis patients, a blood sample was obtained before the second session of the week.
Special attention was paid to those parameters measured by different methods. Particularly, intact parathyroid hormone (iPTH) was corrected using an established conversion method [23] . High-sensitivity C-reactive protein (hs-CRP) and 25-hydroxyvitamin D were both analysed in a centralized laboratory; hs-CRP was determined by the immunoturbidimetric method (Roche/Hitachi modular analytics) and 25-hydroxyvitamin D levels by ELISA (IDS, UK).
iPTH concentrations were categorized according to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for each renal stage [24] , comparing the extreme groups with the target levels.
The Modification of Diet in Renal Disease four-variable equation was used to estimate the glomerular filtration rate (GFR), defining three CKD stages: stage 3 GFR, 60-30 mL/min/ 1.73 m 2 ; stages 4-5, GFR <30 mL/min/1.73 m 2 and dialysis.
Statistical analysis
All analyses were conducted stratified by CKD stage, because many of the potential predictive factors and confounders show a high variation along the CKD spectrum (i.e. phosphate and PTH levels are relatively normal in the early stages, whereas in the late stages those levels increase sharply. In contrast, vitamin D levels are relatively stable until they decrease in dialysis patients). Descriptive analysis included absolute and relative frequencies for qualitative variables, compared by Pearson v Factors predicting accelerated CCIMT progression were estimated by fitting a multivariate logistic regression model for each CKD stage. To avoid the overrepresentation of nonaccelerated progressors, sampling weights were assigned to each group.
Special attention was paid to non-linear relationships, evaluated by linear spline models with different knots (i.e. body mass index on dialysis and iPTH in all stages). Highly skewed variables were log-transformed before inference testing in regression models (i.e. hs-CRP and 25-hydroxyvitamin D). Strongly correlated explanatory variables were also analysed, leaving those that best fit the model [i.e. systolic blood pressure versus pulse pressure and low-density lipoprotein (LDL) cholesterol versus total cholesterol].
All multivariate analyses were adjusted for available variables based on the existing cardiovascular risk literature and for specific CKD factors that may play a role in CCIMT progression, according to CKD stage.
Models for CKD stage 3 and stages 4-5 were adjusted for age, sex, smoking (current and former versus non-smokers), diabetes, body mass index, systolic blood pressure, LDL and high-density lipoprotein (HDL) cholesterol, log-transformed hs-CRP, total calcium, phosphorus, log-transformed 25-hydroxyvitamin D and ranges of iPTH concentrations (using as a reference the KDOQI-recommended target range).
The model for CKD stage 5D was adjusted for age, sex, smoking (current and former versus non-smokers), diabetes, body mass index in tertiles (reference middle tertile), systolic blood pressure, LDL and HDL cholesterol, log-transformed hs-CRP, albumin, total calcium, phosphorus, log-transformed 25-hydroxyvitamin D, ranges of iPTH concentrations (using as reference the KDOQI-recommended target range) and time on dialysis (months).
Specific multiplicative interaction effects between sex and explanatory variables were tested and included in the model only if statistically significant, according to the likelihood ratio test. The calibration of the models was assessed using the Hosmer-Lemeshow v 2 test. Statistical significance was set at a P-value <0.05. All analyses were performed using the SPSS software (version 21).
R E S U L T S
Baseline characteristics according to CKD stage
Demographic and clinical data are depicted in Table 1 . Age and body mass index decreased significantly in more advanced CKD stages. Furthermore, the percentage of men was higher in stage 3 and decreased in more advanced CKD stages.
Traditional cardiovascular risk factors (diabetes, hypertension and dyslipidaemia) were common in stages 3 and 4-5 and decreased significantly in stage 5D. Altered mineral metabolism parameters (hyperphosphataemia, hyperparathyroidism, hypovitaminosis D) were more evident in more advanced CKD stages.
2-year progression in CCIMT
CCIMT at baseline was significantly higher in stage 3 than in stages 4-5 or 5D. The median CCIMT progression rate was Figure 2 shows the mean values of CCIMT at baseline and the median changes after follow-up, according to sex and CKD stage. The mean CCIMT at baseline was significantly higher in men in stages 3 and 4-5 CKD, whereas the yearly change of the median CCIMT was greater among men on dialysis.
Baseline characteristics according to group of progression and CKD stage
The characteristics between groups of accelerated and nonaccelerated progressors by CKD stage are given in Table 2 . Across all CKD stages, accelerated progressors were on average 4-6 years older and had a higher prevalence of carotid plaque at bifurcation or internal carotid segments than non-accelerated progressors. In individuals in stage 3, no significant differences were found between groups in any of the other variables analysed. In stages 4-5, accelerated progressors were more likely to be diabetics and have higher systolic blood pressure and lower serum 25-hydroxyvitamin D levels than non-accelerated progressors. In stage 5D, accelerated progressors were more frequently men, with greater body mass index and higher serum phosphorus; in addition, most of them were taking vitamin D supplements.
Predictors of accelerated CCIMT progression
Traditional risk factors. After adjustment for potential confounders (Table 3) , age was independently associated with an accelerated progression across all CKD stages. Interaction effects were found between LDL cholesterol, HDL cholesterol and sex in stage 3. Among women, LDL was positively associated with accelerated progression, whereas HDL was inversely related to accelerated progression (Supplementary data, Figure S1 and Table S1 ).
Non-traditional risk factors. Serum phosphorus was independently associated with accelerated CCIMT progression among individuals in stages 3 and 5D, and 25-hydroxyvitamin D was inversely associated with accelerated progression in stages 4-5. Figure 3 shows a U-shaped relationship between iPTH levels and accelerated progression across all CKD stages, reaching statistical significance in individuals with iPTH levels >110 pg/ mL in stages 4-5 and among those in stage 5D with serum iPTH <150 pg/mL or >300 pg/mL.
The potential confounding effect of the treatment with erythropoietin or intravenous iron was tested and disregarded.
D I S C U S S I O N
This longitudinal study shows for the first time a strong and independent relationship between serum phosphorus, 25-hydroxyvitamin D and iPTH levels with accelerated CCIMT progression in individuals with moderate to end-stage renal disease without previous CVD. In our study, the CCIMT change cut-off value to define accelerated progression (0.0425 mm/ year) is clearly higher than the normal rate in the general population (defined in several studies to be between 0.0018 and 0.006 depending on sex) [25] [26] [27] . Furthermore, a change of 0.035 mm/year has been defined as significantly increasing the risk of future cardiovascular events [28] . The annual overall CCIMT change of 0.024 mm is in agreement with other studies in renal patients [9, 18] and other high-risk populations, such as type 2 diabetic patients [29] . We did not find any differences in CCIMT progression between CKD stages, in contrast with a study conducted by Desbien et al. [9] , which found an effect of renal function on IMT progression. This discrepancy might be explained by the differences in the cohort, as the NEFRONA cohort is composed of younger individuals without prior CVD. When the median change in progression was stratified by sex, it was significantly higher in male than in female dialysis patients. In further multivariate analysis, being male was an independent factor predicting accelerated progression in dialysis. This fact could explain, at least in part, previous results showing an independent and significant effect of male sex on cardiovascular events in dialysis patients [30] . However, whether CCIMT progression can predict future events remains to be determined, as controversial results have been published [9, 31] .
In the present study, age has been found to be one of the most consistent factors predicting CCIMT progression, as it has been reported in numerous studies [9, 18] . Thus, age remains the only factor that predicts accelerated progression of IMT across all CKD stages.
In the general population, IMT progression can also be partly explained by the presence of lipid disorders [32] . However, the relationship between serum cholesterol and CVD is more complex in patients with CKD, probably due to the cholesterol-lowering effect of systematic inflammation, which increases as GFR decreases [33] . Indeed, three large randomized clinical trials have failed to show a beneficial effect of lipidlowering therapy in reducing mortality in dialysis patients despite a significant reduction in LDL [34] . In our study, no effect of LDL or HDL cholesterol levels was found in stages 4-5 or in dialysis patients. Even so, in stage 3, higher levels of LDL and lower levels of HDL predicted accelerated atherosclerosis among women. Our findings are similar to previous studies in which dyslipidaemia was associated with increased IMT values in the early stages of renal disease [17, 35] . Furthermore, the differential effects of lipids on IMT depending on sex have been previously demonstrated [36] .
One of the most important results of this study is the finding that specific parameters of mineral metabolism play a key role in the rapid development of subclinical atheromatosis. We found that serum phosphorus contributes to the accelerated CCIMT progression in CKD stage 3 and in dialysis. It has been reported that phosphorus load, even in the absence of outright hyperphosphataemia, could be an important promoter of atheromatosis [16, 37] , and several studies have correlated serum phosphorus levels with increased cardiovascular risk in dialysis patients [13, 38] .
It is noteworthy that we found an independent association between serum PTH and accelerated progression of CCIMT. Although the tendency for iPTH levels to follow a U-shaped curve is present in all stages, it only reached statistical significance in dialysis patients and in patients with levels over the recommended target in stages 4-5. The fact that the KDOQIproposed targets are not easily achieved is a common issue that The mean CCIMT at baseline was increased in men compared with women in CKD stage 3 and CKD stages 4-5 (*P < 0.05). The median change in CCIMT was increased in men compared with women in CKD stage 5D (*P < 0.05). Values expressed as mean 6 standard deviation, median (interquartile range) or number of participants (%). Carotid plaque indicates the presence of plaque at the bifurcation or internal carotid segments.
NA, not assessed. has been previously reported [11] . It has also been documented that both low and high serum iPTH increase the risk of mineral metabolism disturbances, soft tissue calcifications and cardiovascular mortality in dialysis patients [13, 14] . Nonetheless, a few studies have looked into the role of iPTH on IMT [39, 40] . Blondon et al. [39] evaluated the associations of PTH and 25-hydroxyvitamin D in the progression of carotid IMT after 9.4 years of follow-up in 3251 subjects from the Multi-Ethnic Study of Atherosclerosis and they found no evidence of an association between these hormones and progression. Reis et al. [40] also failed to find an association between PTH and carotid IMT in a community-based cohort study of 654 participants. However, both studies were general population-based cohorts with much lower levels of PTH than the ones reached in our CKD population, and that may partly explain the discrepancies with our results. In fact, Choi et al. [41] found an association between PTH and carotid IMT among postmenopausal women, and a recent study based on a CKD cohort including iPTH concentrations when assessing IMT demonstrated a regression of IMT after renal transplantation, showing a risk reduction when parameters such as iPTH and phosphorus were corrected [15] . The underlying mechanisms by which iPTH affects IMT progression are complex and multifactorial. Indeed, iPTH receptors have been found in endothelial cells [42] and smooth muscle cells [43] . Thus, on the one hand, lower iPTH receptor activation in vascular smooth muscle cells could enhance IMT progression by a WNT-mediated pathway [44] . On the other hand, high iPTH levels could indirectly increase IMT by activating local production of active vitamin D, which has also been shown to increase proliferation of the medial layer [45] . In endothelial cells, iPTH may also have dual effects on IMT, because it can increase not only nitric oxide production, but also RAGE and IL-6 [46] . Finally, the effect of vitamin D is also of interest. A role for low levels of 25-hydroxyvitamin D has been found only in stages 4-5. Although bivariate analysis showed a similar difference in 25-hydroxyvitamin D levels in dialysis patients, the significance of the effect disappeared in subsequent multivariate analysis. Nevertheless, the fact that vitamin D treatment was associated with CCIMT progression might hide the potential benefit of the effect of 25-hydroxyvitamin D. It has long been known that endothelial and vascular smooth muscle cells also express vitamin D receptors and that its activation shows potential benefits in cardiovascular health [47] . Moreover, clinical studies have shown a strong association between vitamin D levels and cardiovascular mortality in renal patients [48] . In our study, the absence of a predictive value of serum 25-hydroxyvitamin D in stage 5D may point to a possible lack of effects of native vitamin D supplementation in atherosclerosis progression in dialysis patients.
Although the current study provides relevant data regarding the relationship between a wide range of potential risk factors for atheromatosis and IMT progression, the results should be interpreted within the context of exploratory research about accelerated CCIMT progression, showing several limitations. First, the short follow-up period presumes small changes in CCIMT and may have prevented us from obtaining associations among other meaningful factors studied. Nevertheless, the assessment of accelerated progression avoids in part this limitation, helping us to understand which factors predict a greater change in IMT. Second, the assessment of the CCA could lead us to find factors more related to this proximal area, historically associated with a higher shear stress. However, CCIMT represents a more accurate measurement than other segments of the vessel wall [21, 49] . In addition, unmeasured confounding parameters, such as fibroblast growth factor 23 levels, impede us in making a comprehensive analysis of all known factors affecting mineral metabolism. Finally, misclassification owing to measurement error, which is susceptible to random error and short-term variability, and residual confounding due to categorical transformations might bias the results towards the null.
Despite these limitations, the present study has several strengths. The NEFRONA cohort has an adequate sample size and centralization of analytical parameters and image readings. The absence of prevalent CVD together with an adjustment for a wide range of potential confounders, which are concomitant and often overlooked, may allow us to identify independent associations towards enhancing the current knowledge of the underlying mechanisms of atherogenesis in CKD.
In summary, the present study demonstrates that independent of traditional cardiovascular risk factors, specific factors related to CKD appear to be relevant, suggesting a potential role of serum phosphorus, vitamin D and iPTH concentrations in the accelerated subclinical atheromatosis process, which also begins in the earlier stages of CKD.
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